Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport-Reference-Cited by-同舟云学术

Dipeptidyl peptidase 4 inhibitor anagliptin ameliorates hypercholesterolemia in hypercholesterolemic mice through inhibition of intestinal cholesterol transport

Published:2018-06-05 Issue:6 Volume:9 Page:1261-1269
ISSN:2040-1116
Container-title:Journal of Diabetes Investigation
language:en
Short-container-title:J Diabetes Investig

Author:

Goto Moritaka¹^ORCID,Furuta Shinji¹,Yamashita Satoko¹,Hashimoto Hiroyuki¹,Yano Wataru²,Inoue Noriyuki²,Kato Noriaki¹,Kaku Kohei³

Affiliation:

1. Pharmaceutical Research Laboratories; Sanwa Kagaku Kenkyusho Co., Ltd.; Mie Japan

2. Tokyo New Drug Research Laboratories; Kowa Co., Ltd.; Tokyo Japan

3. Department of General Internal Medicine 1; Kawasaki Medical School; Okayama Japan

Publisher

Wiley

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12860/fullpdf

Reference34 articles.

1. Lipid-lowering therapy in diabetes mellitus;Niemeijer-Kanters;Neth J Med,2001

2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome;Nesto;Am J Cardiovasc Drugs,2005

3. Lipids and CVD management: towards a global consensus;Ballantyne;Eur Heart J,2005

4. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

5. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations;Nauck;J Clin Endocrinol Metab,1993

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification of novel prognostic targets in acute kidney injury using bioinformatics and next generation sequencing data analysis;2024-03-17

2. The Role of Apolipoproteins in the Commonest Cancers: A Review;Cancers;2023-11-24

3. Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy;Journal of Atherosclerosis and Thrombosis;2022-01-01

4. Decrease of dipeptidyl peptidase 4 activity is associated with weight loss after bariatric surgery;Obesity Surgery;2021-02-04

5. Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy;Cardiovascular Diabetology;2020-06-15